3 Ways We’re Supporting the Blood Cancer Community

Each person impacted by blood cancer, whether they are a patient, caregiver, family member or friend, is another reason our researchers work every day to advance the science in hematology. 

It is this community of people, fighting blood cancer, that we take time to recognize each September during National Blood Cancer Awareness Month, and who we strive to support year-round in meaningful ways.

We have long held the belief that partnership and collaboration are key to advancing care. It is in this spirit that we are sharing three areas of focus in our efforts to support the blood cancer community:

1. Joining together. This fall, we begin our national sponsorship of The Leukemia & Lymphoma Society Light The Night Walks – a series of events across the country that shine a light on the impact of blood cancer.

Many AstraZeneca employees will join the approximately one million people from all over the U.S. who are walking to support those affected by blood cancer. We believe there is strength in numbers – and we recognize that as individuals, and as organizations, we must come together in support of the more than 200,000 people in the U.S. who are expected to receive a blood cancer diagnosis this year, adding to the 1.3 million Americans who currently live with, or are in remission from blood cancer.

2. Increasing understanding. As a company that strives to be a trusted partner for the community, we recognize the importance of education in understanding blood cancer and the need for resources to support those impacted, whether they be patients or caregivers.

Blood cancer refers to over 130 types of cancer and related disorders of the blood, bone marrow or lymph nodes, including leukemia, lymphoma and multiple myeloma. Critical functions to human health are performed by blood cells, such as fighting off infections and preventing serious bleeding. Blood cancer typically begins in bone marrow, where blood cells are made – once blood cells become cancerous, the uncontrolled growth of divergent cells can affect both production and ability to function.

Throughout National Blood Cancer Awareness Month, we will be sharing educational information on social media to help increase awareness and drive the conversation. But our efforts do not end with September. We aim to show our commitment year-round, every day – working to raise awareness and bring important news as it happens about recent advancements in the science of hematology directly to those who need it most.

3. Advancing the science in hematology. As we look back on some of the recent milestones we have accomplished, we are very proud of the rapid progress we have made in hematology in just a little over two years. While we may still be at the beginning of our ambitious journey in hematology, through our strategic partnerships we are already delivering transformational therapies to enhance and extend the lives of people living with blood cancer.

We recognize there is far more to be done. There are still critical gaps in treating and caring for patients with blood cancer, which is why we continue to prioritize the development of innovative therapies. Our company is dedicated to collaborating with like-minded, science-led organizations and our researchers are driven to follow the science, with a robust development programs in multiple types of blood cancer.

During National Blood Cancer Awareness Month and year-round, follow along with @AstraZenecaUS on Twitter and AstraZeneca US Community Connections on Facebook for updates in this space.